Abstract
BackgroundThere is an unmet clinical need to identify an effective conventional adjuvant immunosuppressive agent in the treatment of large vessel giant cell arteritis. Traditionally the therapeutic approach has employed prolonged...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
